Home › Steatotic Liver Disease › NCT05720663

Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

Adult patients with presence of NAFLD associated cirrhosis.

* Cirrhosis: biopsy confirmed or Agile F (F4) score \> 0.45
* NAFLD as an etiology of liver disease will be determined based on presence of any of the following:

  * Biopsy showing \>5% steatosis or
  * CAP \> 280 dB/m or MR-PDFF\>5%
  * If CAP \< 280 dB/m or MR-PDFF \<5%, then must have type 2 diabetes and or 2 or more features of metabolic syndrome for 5 years (cryptogenic cirrhosis)

Exclusion Criteria:

* Refusal to consent
* Alcohol use \> 14/21 gm/week cutoff
* Other causes of chronic liver disease
* MELD \> 12
* Hepatic and extrahepatic cancers expected to limit life expectancy \< 2 yrs
* prior hepatic resections, TIPS, splenic embolization
* prior decompensation events
* inability to fit into MRI (failed hula-hoop test)
* general contraindication for MRI contrast (GFR \< 30 ml/min)
* contraindications for MRI
* pregnancy
* acute kidney injury
* reduced kidney function (GFR \<30ml/min)

About the study

Nonalcoholic Steatohepatitis (NASH) is a condition with increased amount of fat, inflammation and scarring in the liver. In compensated cirrhosis, the liver is coping with this damage and maintaining its important functions. Decompensation occurs when the liver becomes unable to perform all of its functions adequately. Variceal hemorrhage (bleeding from abnormal vessels in the liver called varices), Ascites (abnormal build-up of fluid in the abdomen), and Encephalopathy (brain confusion as a result of the liver not being able to get rid of toxic substances) are three symptoms of liver decompensation.

The purpose of this research study is to investigate better ways to routinely monitor the condition of patients with NASH with compensated cirrhosis and to better pinpoint the development of decompensation in the livers of these patients.

What is being tested

• Standard of care (other)

Sponsor: Virginia Commonwealth University · Participants: 240 · Started: Apr 19, 2023

Contact the study team

• Mohammad S Siddiqui, MD · Phone: 804-828-4060

Official record on ClinicalTrials.gov — NCT05720663

Locations in the U.S.

Conditions

• Steatotic Liver Disease

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.